A small trial of 60 patients conducted by in Copenhagen showed that injecting mesenchymal stem cells directly into the heart muscle of the left ventricle provided some improvements for cardiac patients with severe heart failure.  Compared with the placebo injection group, those who received the stem cell injections had significant gains in end-systolic volume, left ventricular ejection fraction, stroke volume, and new cardiac muscle within six months.  The results were presented at a conference of the American College of Cardiology and have not been peer reviewed. Larger future trials will be needed to determine if the improvements can translate to better clinical outcomes for patients. 
[1] Neale, Todd, "ACC: Stem Cell Injections to Heart Promising," medpage TODAY, April 4, 2014.

Hospira has announced a recall of blood sets containing an incorrect set component (list number 11241-03, lot numbers 28005-5H and 34100-5H) distributed between May 2013 - December 2013.  The Hemostat Dual Channel Plum Set is designed to administer blood and blood products via the Plum infusion pump. If the Plum infusion pump is used with the affected product, the blood product will be delivered at its intended dosage and there is no risk of over-delivery. If the affected product is removed from the Plum infusion pump and used in a gravity infusion, there is a risk that over-delivery may occur. Over-delivery of blood products in the populations at greatest risk (e.g. neonates, patients with heart and/or kidney failure, and other patients with conditions associated with susceptibility to volume overload) may result in injuries that require medical intervention. These injuries are expected to fully resolve with medical intervention.

[1] FDA Safety Information, "Hospira Hemostat Dual Channel Plum Set: Recall-Risk of over-delivery of blood products," (March 18, 2014).